- 抗体工程 -
Today’s protein scientists need to be creative and think outside the box. As standard monoclonal antibodies give way to new and diverse therapeutic modalities, protein scientists have to develop strategies that can better engineer these complex molecules, and improve their targeting, specificity, binding, intracellular penetration and bioactivity.

PEGS Europe’s 3rd Annual Engineering Antibodies invites scientists to present their creativity in designing novel antibody formats or alternative platforms, and in leveraging strategies and technologies to overcome challenging intracellular and membrane targets.


Preliminary Agenda

ANTIBODIES AGAINST INTRACELLULAR AND CHALLENGING TARGETS

KEYNOTE PRESENTATION: Grp 94, an Intracellular Target of Antibody-Based Immunotherapy of Malignant Diseases – Opportunities and Challenges
Soldano Ferrone, MD, PhD, Professor, Surgery, Massachusetts General Hospital, Harvard Medical School

Engineering Alphabodies to Target Intractable Intracellular Cancer Targets
Yvonne McGrath, PhD, CSO, Complix

Generating Potent and Selective Inhibitors of Kv1.3 Ion Channel by Fusing Venom Derived Mini Proteins into Peripheral CDR Loops of Antibodies
Aneesh Karatt-Vellatt, PhD, Group Leader, Antibody and Protein Engineering, IONTAS Ltd.

NOVEL FORMATS AND ALTERNATIVE PLATFORMS

Use of Small and Stable Antibody Scaffold Fv-clasp to Facilitate Structural Studies of Drug-Target Molecules
Junichi Takagi, PhD, Professor, Laboratory, Protein Synthesis and Expression, Institute for Protein Research, Osaka University

Multi-Specific, Multi-Valent and Bi-Paratopic Nanobodies: Progress toward the Clinic
Carlo Boutton, PhD, Director, Technology & Information Management, Ablynx NV

Development of Novel T-Cell Receptor Bispecifics with Highly Potent Activity against Tumor-Specific HLA Ligands
Sebastian Bunk, PhD, Research Director, Immunology, TCR Engineering and Bispecifics, Immatics

Development of mRNA-Encoded Bispecific Antibodies Targeting Solid Tumors
Hayat Bähr-Mahmud, PhD, Deputy Head, Bispecific Antibodies, BioNTech

V565 Is a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
Kevin Roberts, PhD, Senior Scientist, VHsquared

STRATEGIES TO IMPROVE TARGETING, AFFINITY AND BIOACTIVITY OF MOLECULES

Targeting the Matrix Metalloproteinase (MMP)-14/MMP-2/integrin avb3 Axis with Multispecific N-TIMP2-Based Antagonists for Cancer Therapy
Niv Papo, PhD, Group Leader, Assistant Professor, Biotechnology Engineering, Ben-Gurion University

Collecting Structural Data to Improve Predictions of Protein-Protein Interface Mutagenesis
Samuel Coulbourn Flores, Docent, Dean, Swedish National Graduate School in Medical Bioinformatics, Department of Biochemistry and Biophysics, Stockholm University

The Molecular Landscape of the Immune Response Following Treatment with Biologics
Yariv Wine, PhD, Assistant Professor, School of Molecular Cell Biology and Biotechnology, Tel Aviv University

EMERGING TECHNOLOGIES IN ANTIBODY ENGINEERING AND DISCOVERY

From Antibody-Targeted Toxins to Gene Editing: Disruption of Diphthamide Synthesis Genes and Resulting Toxin Resistance as a Robust Technology for Quantifying and Optimizing CRISPR/Cas9 Approaches
Ulrich Brinkmann, PhD, Expert Scientist, Molecular Engineering, Roche

High-Throughput Antibody Engineering in Mammalian Cells by CRISPR/Cas9-Mediated Homology-Directed Mutagenesis
Sai Reddy, PhD, Assistant Professor, Biosystems Science and Engineering, ETH Zurich

A Case Study in Adaptability: Exemplification of the Power of UCB’s Core Discovery Platform through the Discovery of a Potent Anti-Tau Antibody
Dale Starkie, PhD, Senior Scientist, UCB Celltech

Sponsored Presentation

Antibody Protein Sequencing with Mass Spectrometry
Mingjie Xie, CEO, Rapid Novor Inc




* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English